ReviewThe Journal of membrane biology2022
Recent Developments in Single-Virus Fusion Assay.
Review in The Journal of membrane biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Conserved Fusion Peptide Sequence of SARS-CoVs is Insensitive to CaThe Journal of membrane biology · 2026Article
- A Fluorogenic Pseudoinfection Assay to Probe Transfer and Distribution of Influenza Viral Contents to Target Vesicles.Analytical chemistry · 2024Article
- Preface to Special Issue on Protein-Mediated Membrane Remodeling.The Journal of membrane biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral infection is a global health hazard. A crucial step in the infection cycle of enveloped viruses is the fusion of viral and host cellular membranes, which permits the transfer of the viral genome to the host cells. Membrane fusion is a ubiquitous process involved in sperm-egg fusion, exocytosis, vesicular trafficking, and viral entry to host cells. While different protein machineries catalyze the diverse fusion processes, the essential step, i.e., merging of two lipid bilayers against a kinetic energy barrier, is the same. Therefore, viral fusion machineries/pathways are not only the sites for antiviral drug development but also serve as model fusogens. Ensemble-based spectroscopic approaches or bulk fusion assays have yielded valuable insights regarding the fusion processes. However, due to the stochastic nature of the fusion events, ensemble-based assays do not permit synchronization of all the fusion events, and the molecular steps leading to fusion pore opening cannot be resolved entirely and correlated with the structural changes in viral fusion proteins. Several single-virus fusion assays have been developed to circumvent these issues. The review describes the recent advancements in single-virus/particle fusion assays using the Influenza virus as a paradigm.
Indexed as
Identifiers
36173449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.